Compare Abeona Therapeutics Inc (ABEO) vs The Coca-Cola Co K (KO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs The Coca-Cola Co K — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while The Coca-Cola Co K trades at $83.98 (market cap $361.62B). The key difference: The Coca-Cola Co K is far larger — about 968.7× Abeona Therapeutics Inc's market cap, and The Coca-Cola Co K pays a 2.52% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | KO | |
|---|---|---|
Market Cap | $373.32M | $361.62B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $84.14 |
52-Week Low | $4.17 | $65.67 |
Enterprise Value | $228.22M | $391.69B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Coca-Cola (KO) trades at $83.90, up 1.13% on the day, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals, including a 27.8% net income margin and consistent earnings beats in recent quarters. Recent news highlights steady demand trends and dividend reliability, with the company increasing its dividend for 64 consecutive years.
The outlook remains positive with a consensus price target of $88.14, offering ~5% upside. Key risks include regional demand divergence and high valuation multiples. Analyst sentiment is predominantly bullish, supported by strong cash flow and brand strength, though investors should monitor execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
